Identification of ligands binding specifically to inflammatory intestinal mucosa using phage display

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 4, 2007, Pages 286-289

  Takagi, Tamaki ^a,b   Arisawa, Tomiyasu ^b   Yamamoto, Kazumasa ^c   Hirata, Ichiro ^b   Nakano, Hiroshi ^b   Sawada, Makoto ^c  

^a School of Medicine ^*  (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

Author keywords

Inflammatory bowel; Phage display; Phd C7C phage; Targeting ligands

Indexed keywords

AMINO ACID; PEPTIDE LIBRARY; SERYLGLUTAMINYLSERYLHISTIDYLPROLYLARGINYLHISTIDINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOPANNING; CLONE; ENTERITIS; INTESTINE ISCHEMIA; INTESTINE MUCOSA; LIGAND BINDING; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; REPERFUSION INJURY; SEQUENCE ALIGNMENT;

ADSORPTION; AMINO ACID SEQUENCE; ANIMALS; BACTERIOPHAGES; BINDING SITES; BINDING, COMPETITIVE; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LIGANDS; MALE; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; PEPTIDE LIBRARY; REPERFUSION INJURY;

EID: 33846959142     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04563.x     Document Type: Article

References (26)

1. Shinozaki M, Suzuki K, Sawada T, Tsuno N, Higuchi Y, Muto T. Steroid complications and surgery in intractable ulcerative colitis. J. Gastroenterol. 1998; 33: 196-200.
2. Kusunoki M, Moslein G, Shoji Y et al. Steroid complications in patients with ulcerative colitis. Dis. Colon Rectum 1992; 35: 1003-9.
3. Hanauer SB, Feagan BG, Lichtenstein GR et al. ACCENT I study group: Maintenance infliximab for Crohn's disease. The ACCENT I randomized trial. Lancet 2002; 359: 1541-9.
4. Feagan BG, Yan S, Bala M, Bao W, Lichitenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am. J. Gastroenterol. 2003; 98: 2232-8.
5. Sands BE, Blank MA, Patel K, van Deventer SJ. ACCENT II study. Long-term treatment of rectovaginal fistulas in Crohn's disease: Response to infliximab in the ACCENT II study. Clin. Gastroenterol. Hepatol. 2004; 2: 912-20.
6. Hanauser SB, Wanger CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2004; 2: 542-53.
7. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission inpatients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am. J. Gastroenterol. 2004; 99: 91-6.
8. Noman M, Baert F, Get DH et al. HACA formation after infliximab (Remicade™) treatment in Crohn's disease is clearly associated with infusion reactions. Gastroenterology 2001; 120: A621 (Abstract).
9. Helbling D, Bretbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumor necrosis factor therapy. Eur. J. Gastroenterol. Hepatol. 2002; 14: 1393-5.
10. De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: A possible healthcare-associated case? Infect. Control Hosp. Epidemiol. 2003; 24: 477-82.
11. Sarzi-Puttini P, Ardizzone S, Manzionna G et al. Infliximab-induced lupus in Crohn's disease: A case report. Dig. Liver Dis. 2003; 35: 814-17.
12. Megison SM, Horton JW, Chao H et al. A new model for intestinal ischemic in the rat. J. Surg. Res. 1990; 49: 168-73.
13. Riaz AA, Wan MX, Schäfer T et al. Allopurinol and superoxide dismutase protect against leucocyte-endothelium interactions in a novel model of colonic ischemia-reperfusion. Br. J. Surg. 2002; 89: 1572-80.
14. Kolonin MG, Sun J, Do KA et al. Synchronous selection of homing peptides for multiple tissue by in vivo phage display. FASEB J. 2006; 20: 979-81.
15. Duerr DM, White SJ, Schluesener HJ. Identification of peptide sequences that induce the transport of phage across the gastrointestinal mucosal barrier. J. Virol. Methods 2004; 116: 177-80.
16. Chen Y, Sakata M, Ojala JR et al. A phage display screen and binding studies with acetylated low density lipoprotein provide evidence for the importance of the scavenger receptor cystein-rich (SRCR) domain in the ligand-binding function of MARCO. J. Biol. Chem. 2006; 281: 12 767-75.
17. Lang J, Zhan J, Xu L, Yan Z. Identification of peptide mimetics of xenoreactive alpha-Gal antigenic epitope by phage display. Biochem. Biophys. Res. Commun. 2006; 344: 214-20.
18. Luzzago A, Felici F, Tramontano A, Pessi A, Cortese R. Mimicking of discontinuous epitopes by phage-displayed peptides, I. Epitope mapping of human H ferritin using a phage library of constrained peptides. Gene 1993; 128: 51-7.
19. Higgins LM, Lambkin I, Donnelly G et al. In vivo phage display to identify M cell-targeting ligands. Pharm. Res. 2004; 21: 695-705.
20. Fiocchi C. Inflammatory bowel disease pathogenesis: Therapeutic implications. Chin. J. Dig. Dis. 2005; 6: 6-9.
21. Lambkin I, Pinilla C. Targeting approaches to oral drug delivery. Expert Opin. Biol. Ther. 2002; 2: 67-73.
22. Zou MJ, Cheng G, Okamoto H et al. Colon-specific drug derivery systems based on cyclodextrin prodrugs: In vivo evaluation of 5-aminosalicylic acid from its cyclodextrin conjugates. World J. Gastroenterol. 2005; 11: 7457-60.
23. Guliyeva U, Oner F, Ozsoy S, Haziroglu R. Chitosan microparticles containing plasmid DNA as potential oral gene delivery system. Eur. J. Pharm. Biopharm. 2006; 62: 17-25.
24. Metz T, Jones ML, Chen H et al. A new method for targeted drug delivery using polymeric microcapsules: Implications for treatment of Crohn's disease. Cell. Biochem. Biophys. 2005; 43: 77-85.
25. Vallance BA, Gunawan MI, Hewllett B et al. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2005; 289: G116-28.
26. Palumbo RN, Wang C. Bacterial invasin: Structure, function, and implication for targeting oral gene delivery. Curr. Drug Deliv. 2006; 3: 47-53.